Company Overview

Standard BioTools Inc. is a life sciences tools company that develops and manufactures instruments, reagents, and software used in high-dimensional biological analysis. The company operates primarily in the research and clinical research segments of the biotechnology and pharmaceutical industries, supporting applications such as immunology, oncology, cell therapy, and proteomics. Its core offerings enable researchers to analyze cells and proteins at scale with high sensitivity, serving academic institutions, pharmaceutical and biotechnology companies, and clinical research organizations.

The company’s primary revenue drivers are its mass cytometry, microfluidics, and proteomics platforms, which generate recurring revenue through consumables, reagents, and service contracts in addition to instrument sales. Standard BioTools is positioned around differentiated, high-parameter analysis technologies that allow simultaneous measurement of dozens to thousands of biological signals. Founded in 1999 as Fluidigm Corporation, the company rebranded to Standard BioTools Inc. in 2022 following a strategic shift toward becoming a multi-platform life sciences tools provider, most notably through its acquisition of SomaLogic, Inc. in 2023.

Business Operations

Standard BioTools operates through distinct but complementary business lines focused on analytical instrumentation and consumables. Its principal operating segments include Mass Cytometry, Microfluidics, and Proteomics, each contributing to instrument sales and recurring consumable revenue. The Mass Cytometry business is centered on the CyTOF platform, which enables high-dimensional single-cell analysis, while Microfluidics supports genomic applications such as PCR and gene expression analysis. The Proteomics segment is driven by the SomaScan platform, which allows large-scale protein measurement from biological samples.

The company conducts sales and support operations across North America, Europe, and Asia-Pacific, with manufacturing and research functions primarily based in the United States. Standard BioTools controls proprietary instrumentation, assay chemistries, and analytical software, creating switching costs and customer lock-in. Key subsidiaries include SomaLogic Operating Co., Inc., which operates as the backbone of the company’s proteomics business. The company also maintains strategic collaborations with pharmaceutical companies and research institutions to expand the application base of its technologies.

Strategic Position & Investments

Standard BioTools’ strategy is focused on expanding its presence in high-growth, high-dimensional biology markets by integrating complementary platforms and increasing recurring revenue. A cornerstone of this strategy was the acquisition of SomaLogic, Inc., which significantly broadened the company’s addressable market by adding large-scale proteomics capabilities. This transaction shifted the company toward a more diversified revenue mix and increased its relevance in biomarker discovery and translational research.

The company continues to invest in assay development, automation, and data analytics to enhance platform scalability and ease of use. Emerging areas of focus include single-cell multiomics, proteogenomics, and clinical research applications that bridge discovery and diagnostics. Management has emphasized disciplined capital allocation, cost rationalization, and leveraging shared commercial infrastructure across platforms to improve operating efficiency following its strategic transformation.

Geographic Footprint

Standard BioTools is headquartered in South San Francisco, California, and operates globally through direct sales teams and distributors. The company has a strong presence in North America, which represents its largest revenue base, supported by significant customer adoption among U.S.-based academic and biopharmaceutical researchers. Europe is another major market, with established commercial operations serving research institutions and pharmaceutical companies.

The company also maintains a growing footprint in Asia-Pacific, including markets such as China, Japan, and South Korea, where demand for advanced life sciences research tools continues to expand. Manufacturing, research, and customer support activities are strategically located to support global distribution, and the company’s international operations contribute meaningfully to total revenue and long-term growth potential.

Leadership & Governance

Standard BioTools is led by an executive team with experience across life sciences tools, biotechnology, and diagnostics. The leadership team has articulated a strategic vision centered on platform integration, operational discipline, and long-term value creation through differentiated technology offerings. Governance practices align with U.S. public company standards, with oversight provided by an independent board of directors.

Key executives include:

• Michael Egholm – Chief Executive Officer
• Andrew R. Sides – Chief Financial Officer
• Catherine F. Vigneau – Chief Legal Officer and Corporate Secretary
• Karen S. Urbanek – Chief Human Resources Officer
• Kevin J. Hrusovsky – Strategic Advisor and former Executive Chairman

The leadership philosophy emphasizes scientific innovation combined with commercial execution, with a stated focus on improving profitability while continuing to invest in high-impact research technologies.